Korea Phil Medical Foundation (Chairman Kim Seong-ho) signed an agreement to become the exclusive domestic distributor of AIDOT (CEO Jeong Jae-hoon)’s AI-based cervical cancer screening solution “Cerviray” and its next-generation colposcope camera—the only solution in Korea to have received MFDS Class 3 clinical trial plan approval—and has entered full-scale domestic commercialization procedures.

Korea Phil Medical Foundation is a mid-sized medical foundation ranked No. 1 in Korea in cervical cancer screening market share based on cytology and HPV testing, and when including other tests such as diagnostic pathology and molecular diagnostics, it ranks within the top six in Korea. As of 2021, among 3,500 hospital client accounts in Korea, approximately 1,500 hospitals conduct cervical cytology and HPV testing.

Under this agreement, Korea Phil Medical Foundation will provide magnified cervical imaging examinations upgraded with a next-generation portable colposcope device based on an optical-lens system that it developed together with AIDOT.

In Korea’s cervical cancer field, Cerviray AI is currently the only solution conducting an MFDS Class 3 clinical trial. AIDOT plans to introduce a total cervical cancer screening solution in which AI is formally integrated as soon as it obtains MFDS certification.

This would allow primary and secondary obstetrics and gynecology clinics to offer screening options that satisfy both hospitals and patients at a more reasonable cost than before.

Chairman Kim Seong-ho of Korea Phil Medical Foundation said, “AIDOT is the only company with a systematic solution that, together with IRB approval, is conducting a Class 3 clinical trial using AI for cervical cancer. We highly valued this potential and concluded not only a strategic investment but also an exclusive contract,” adding, “By combining AIDOT’s technological capabilities with Korea Phil Medical Foundation’s know-how in cervical cancer screening, we will do our utmost to contribute to the eradication of cervical cancer and the early-diagnosis market in Korea.”

Published: July 20, 2021 / AI Times / Reporter Jeon Mi-jun